Cytoagencts Inc is a privately held biotech company structured around development of innovative pharmaceutical products to treat cytokine release syndrome (CRS). With CRS having many known causes, indications are of significant unmet medical needs. The lead compound under development at Cytogents is called GP1681 - a Clinical Stage, small-molecule inhibitor of cytokine release in activated human immune cells with a well-established safety record. The compound is delivered orally, is cost-effective and shelf-stable treatment. These combinationof factors make it broadly accessible and an ideal stockpiling candidate. Principals of the firm indicate they are currently targeting indications including COVID-19, CAR-T Cell Therapy, Vaping Induced Lung Injury, and Influenza.
